Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 2Completed 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 153Thoracic 20Gynecologic 17Breast 14Genitourinary 12Head & Neck 8CNS 8Endocrine 6Sarcoma 5Dermatologic 5Other solid neoplasm 4NET 4Plasma cell 2Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 541Precursor Cell Lymphoblastic Leukemia-Lymphoma 310Hematologic Neoplasms 264Leukemia 179Myelodysplastic Syndromes 170Leukemia, Lymphocytic, Chronic, B-Cell 168Lymphoma 101Lymphoma, Non-Hodgkin 94Recurrence 84Neoplasms 83Multiple Myeloma 82Leukemia, Myelogenous, Chronic, BCR-ABL Positive 72Leukemia, Myelomonocytic, Chronic 61Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 58Burkitt Lymphoma 54Leukemia, Biphenotypic, Acute 48Myeloproliferative Disorders 45Lymphoma, Follicular 43Lymphoma, Mantle-Cell 42Lymphoma, Large B-Cell, Diffuse 42Hodgkin Disease 34Lymphoma, B-Cell 32Lymphoma, B-Cell, Marginal Zone 30Leukemia, B-Cell 30Anemia, Refractory, with Excess of Blasts 30Primary Myelofibrosis 28Leukemia, Plasma Cell 23Waldenstrom Macroglobulinemia 22Neoplasm, Residual 21Leukemia, Myeloid, Chronic-Phase 21

Interventions

olutasidenib 1Cytochrome P-450 CYP3A 1Cytochrome P-450 CYP2C9 1Cytochrome P-450 CYP2C8 1Cytochrome P-450 CYP2C19 1Cytochrome P-450 CYP2B6 1Cytochrome P-450 CYP1A2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × Other hematologic neoplasm × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidMyeloidNETOther hematologic neoplasmThoracic

Turcot syndrome, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Laryngeal Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Skin Neoplasms, Stomach Neoplasms, Testicular Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡